BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down – What’s Next?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) gapped down prior to trading on Tuesday . The stock had previously closed at $7.46, but opened at $7.23. BioCryst Pharmaceuticals shares last traded at $7.43, with a volume of 67,628 shares traded.

Analyst Ratings Changes

Several research firms have recently commented on BCRX. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, Barclays increased their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.60.

BioCryst Pharmaceuticals Stock Up 1.1 %

The company’s fifty day moving average price is $7.61 and its 200-day moving average price is $7.41. The stock has a market capitalization of $1.56 billion, a PE ratio of -12.23 and a beta of 1.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. During the same quarter in the previous year, the firm posted ($0.19) EPS. The firm’s quarterly revenue was up 35.1% compared to the same quarter last year. Equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

Institutional Trading of BioCryst Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Deerfield Management Company L.P. Series C grew its holdings in shares of BioCryst Pharmaceuticals by 62.9% during the second quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock valued at $50,279,000 after buying an additional 3,140,804 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of BioCryst Pharmaceuticals by 2.7% in the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock worth $36,776,000 after purchasing an additional 127,708 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 16.9% during the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock valued at $25,369,000 after purchasing an additional 481,359 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of BioCryst Pharmaceuticals by 13.6% during the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock valued at $16,576,000 after buying an additional 261,500 shares during the last quarter. Finally, Rice Hall James & Associates LLC increased its holdings in BioCryst Pharmaceuticals by 4.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock worth $16,444,000 after buying an additional 84,102 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.